What Hyperfine (HYPR) Said on Its Q3 Earnings Call

Key Points

• Record Q3 results: Revenue rose 73% year over year to $6 million, while gross margin reached a record 56.7%. Hyperfine sold 14 Swoop systems, compared with eight a year earlier.
• Losses and cash burn narrowed: Operating loss fell 19% year over year to $7.3 million, and net cash burn declined 29% sequentially to $5.6 million. The company ended the quarter with $37.9 million in cash and reaffirmed its expected runway into 2028.
• Outlook and growth initiatives: Hyperfine maintained its 2026 revenue forecast of $20 million to $22 million and cash burn guidance, while raising the lower end of its gross margin outlook. It is expanding internationally and expects to submit a contrast-imaging application to the FDA by year-end 2026.

Hyperfine NASDAQ: HYPR reported record third-quarter revenue and gross margin, while narrowing its operating loss and reducing cash burn as sales of its portable brain MRI system increased across its U.S. and international markets.

Revenue rose 73% from a year earlier to $6 million for the quarter ended September 30, 2026, and increased 53% from the second quarter. Hyperfine sold 14 Swoop systems, up from eight a year earlier, and reported a record average selling price.

The company reaffirmed its full-year revenue and cash burn forecasts and raised the lower end of its gross margin guidance. President and CEO Maria Sainz said the quarter’s growth came from hospital, office and international sales, with the hospital business remaining its largest commercial vertical.

Margins improve as cash burn declines

Third-quarter gross profit increased to $3.4 million from $1.8 million a year earlier. Gross margin rose to 56.7% from 53.8% in the prior-year period and 50.7% in the second quarter. Chief Administrative Officer and CFO Brett Hale attributed the improvement to higher average selling prices, the mix of Model 2 systems and increased scale.

Operating loss narrowed to $7.3 million, down 19% year over year and 14% sequentially. Research and development expenses declined 3% to $3.9 million, while sales, general and administrative expenses were flat at $6.7 million.

Net loss was $6 million, or 6 cents per share, compared with $11 million, or 14 cents per share, a year earlier. The latest quarter included a $1.5 million non-cash gain from a change in the fair value of warrant liabilities; the prior-year quarter included a $2.3 million non-cash loss.

Net cash burn fell 29% sequentially to $5.6 million, marking the first quarter in which revenue exceeded cash burn. Hyperfine ended September with $37.9 million in cash and cash equivalents and reaffirmed its expected cash runway into 2028, assuming no additional financing or future debt draws. Hale said the company also had up to $25 million in remaining debt facility capacity, subject to loan agreement conditions.

Guidance maintained after record quarter

Hyperfine reaffirmed its 2026 revenue forecast of $20 million to $22 million and its net cash burn guidance of $26 million to $28 million. It narrowed its full-year gross margin outlook to 52.5% to 55%, from 50% to 55% previously.

Revenue for the first nine months of the year was $13.8 million, up 66% from a year earlier, while unit sales increased 64% to 36 systems.

Asked why the company did not raise its revenue forecast after the strong quarter, Hale said the existing range remained appropriate given the size of capital equipment deals and the company’s visibility. Sainz added that a multi-unit system-wide upgrade gave the fourth quarter of 2025 a one-time boost, and that Hyperfine has not historically experienced as pronounced a fourth-quarter effect as some other companies.

Health systems and contrast imaging

Sainz said Hyperfine received new and follow-on orders and placements from health systems during the third quarter. She described a “land-and-expand” approach in which initial placements can lead to additional orders once contracts, approvals and clinical advocates are established.

Initial health-system sales can require procurement, legal, cybersecurity and artificial intelligence reviews, Sainz said. She estimated that follow-on orders from large national systems could take two to three quarters after a first placement, while regional systems may move faster.

Hyperfine also completed enrollment in its Contrast PMR study and remains on track to submit a 510(k) application to the Food and Drug Administration by the end of 2026. Sainz said the company expects a potential clearance around the second quarter or middle of 2027, allowing for possible FDA questions.

Contrast imaging could expand use in operating rooms and make the system more attractive to some neurology offices, Sainz said. She noted that contrast brain MRI in outpatient settings has a dedicated reimbursement code. Hyperfine also said its NEURO PMR study was published in the Journal of Neuroimaging; Sainz reported that portable MRI showed 92% concordance with conventional MRI in identifying pathology in a blinded review, rising to 98% when clinical history was included.

International and wellness opportunities

Hyperfine launched Model 2 in Europe and the U.K. in mid-2026 following CE and UKCA marking and has sold the system in four international markets, Sainz said. Its latest Optive AI software received those markings in October, and the company recently signed an exclusive distribution agreement covering Kuwait and the United Arab Emirates.

Sainz also pointed to emerging interest from memory clinics and wellness, longevity and concierge practices. While Hyperfine is exploring a broader consumer-facing brain wellness offering, she said she would not expect that initiative to generate revenue in 2027, instead looking to 2028 and beyond. The company’s working assumption is to use its existing scanner while developing software and patient-facing reporting.

For 2027 planning, Sainz said Hyperfine is considering how to structure its sales resources across hospital and office markets, but expects only modest investment in commercial capacity. Hale said the company intends to continue pursuing operating leverage while making targeted investments.

About Hyperfine (NASDAQ:HYPR)

Hyperfine, Inc NASDAQ: HYPR is a medical technology company focused on making magnetic resonance imaging more accessible and convenient. The company develops portable, low-field MRI technology designed to bring brain imaging directly to patients in locations such as intensive care units, emergency departments, operating rooms and other point-of-care settings.

Hyperfine's primary product is the Swoop Portable MR Imaging System, a compact MRI platform that can be moved to a patient's bedside.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.